Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective is to analyze peritonitis rate and peritonitis bacteriology as risk factors for loss of residual renal function, technique failure and mortality in chronic kidney disease patients.
Secondary objectives are: To know the current rate of peritonitis in peritoneal dialysis population and to understand the bacteriological profile of peritonitis.
To know the rate and risk factors other than peritonitis involved in the loss of residual renal function.
To analyze the utility of alternative diagnostic tests, such as reagent strips, for early detection of peritonitis when traditional tests are not available.
To analyze the simultaneous measurement of serum creatinine and cystatin-C as alternative measurements of peritoneal clearance and residual renal function.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Incident peritoneal dialysis patients | Patients with chronic kidney disease incident to peritoneal dialysis treatment |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Loss of residual renal function | 25 months | |
| Technique (peritoneal dialysis) failure | Shift to hemodialysis | 25 months |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Death | 25 months |
Inclusion Criteria:Inclusion criteria include: adult patients with signed informed consent given; there should not be selection for age, gender, primary cause of renal disease.
-
Exclusion Criteria:Patients will not be included if they were previously in hemodialysis or received renal transplant. Patients will also be excluded if they are on immunosuppressive therapy, have diagnosis of cancer, or are seropositive for HIV or hepatitis.
-
Not provided
Not provided
Not provided
All patients starting PD as the first dialysis treatment will be considered. Recruitment will take place over a six-months period in hospitals belonging to the Instituto Mexicano de Seguro Social. Inclusion criteria include: adult patients with signed informed consent given; there should not be selection for age, gender, primary cause of renal disease. Patients will not be included if they were previously in hemodialysis or received renal transplant. Patients will also be excluded if they are on immunosuppressive therapy, have diagnosis of cancer, or are seropositive for HIV or hepatitis.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Ramon Paniagua, MD, PhD | Contact | +52-55-56276900 | 21371 | jrpaniaguas@gmail.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Unidad de Investigación Médica en Enfermedades Nefrológicas, Instituto Mexicano del Seguro Social | Mexico City | Mexico City | 06722 | Mexico |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Mar 15, 2019 | |
| Reset | Jun 25, 2019 | |
| Release | Jul 21, 2022 | |
| Reset | Jun 9, 2023 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Mar 15, 2019 | Jun 25, 2019 | |||
| Jul 21, 2022 |
| ID | Term |
|---|---|
| D010538 | Peritonitis |
| ID | Term |
|---|---|
| D059413 | Intraabdominal Infections |
| D007239 | Infections |
| D010532 | Peritoneal Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| Jun 9, 2023 |